You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 22, 2025

CLINICAL TRIALS PROFILE FOR CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Cardene In 5.0% Dextrose In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00325793 ↗ IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status PDL BioPharma, Inc. Phase 4 2004-01-01 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00325793 ↗ IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status OSF Healthcare System Phase 4 2004-01-01 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00528827 ↗ A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of CardeneĀ® I.V. in Pediatric Subjects With Hypertension Withdrawn Facet Biotech Phase 2 2007-09-01 To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
NCT00765648 ↗ Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department Completed EKR Therapeutics, Inc Phase 4 2008-10-01 The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.
NCT00765648 ↗ Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department Completed The Cleveland Clinic Phase 4 2008-10-01 The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cardene In 5.0% Dextrose In Plastic Container

Condition Name

Condition Name for Cardene In 5.0% Dextrose In Plastic Container
Intervention Trials
Hypertension 3
Cerebral Vasospasm 2
Hypotensive Anesthesia 1
Nontraumatic Intracerebral Hemorrhage, Multiple Localized 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cardene In 5.0% Dextrose In Plastic Container
Intervention Trials
Hypertension 3
Vasospasm, Intracranial 2
Cerebral Hemorrhage 2
Hemorrhage 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cardene In 5.0% Dextrose In Plastic Container

Trials by Country

Trials by Country for Cardene In 5.0% Dextrose In Plastic Container
Location Trials
United States 18
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cardene In 5.0% Dextrose In Plastic Container
Location Trials
Massachusetts 2
Texas 2
Ohio 2
Florida 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cardene In 5.0% Dextrose In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Cardene In 5.0% Dextrose In Plastic Container
Clinical Trial Phase Trials
Phase 4 6
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cardene In 5.0% Dextrose In Plastic Container
Clinical Trial Phase Trials
Withdrawn 3
Recruiting 2
Terminated 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cardene In 5.0% Dextrose In Plastic Container

Sponsor Name

Sponsor Name for Cardene In 5.0% Dextrose In Plastic Container
Sponsor Trials
Vanderbilt University Medical Center 2
Boston Medical Center 1
The Cleveland Clinic 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cardene In 5.0% Dextrose In Plastic Container
Sponsor Trials
Other 22
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Cardene In 5.0% Dextrose In Plastic Container

Introduction

Cardene, also known as nicardipine hydrochloride, is a potent calcium channel blocker with significant vasodilator action, commonly used for its antihypertensive properties. This article will delve into the current state of clinical trials, market analysis, and future projections for Cardene In 5.0% Dextrose In Plastic Container.

Clinical Trials Overview

While specific ongoing clinical trials for Cardene In 5.0% Dextrose In Plastic Container are not widely reported in recent sources, it is essential to understand the stability and efficacy of nicardipine hydrochloride in various intravenous solutions.

Stability Studies

Studies on the stability of nicardipine hydrochloride in intravenous solutions indicate that the drug is not stable in certain conditions. For instance, nicardipine hydrochloride is unstable in 5% sodium bicarbonate injection and in PVC bags containing lactated Ringer's injection or 5% dextrose and lactated Ringer's injection. However, it remains stable in glass containers for up to seven days in solutions such as 5% dextrose and 0.9% sodium chloride injection[3].

Implications for Clinical Use

The stability data are crucial for clinical trials and routine clinical use, as they dictate the appropriate storage and administration methods to ensure the drug's efficacy and safety. For example, avoiding PVC containers and using glass containers can help maintain the drug's concentration over time.

Market Analysis

Current Market Dynamics

The market for nicardipine hydrochloride is poised for significant growth driven by increasing demand and favorable market dynamics. The expanding healthcare sector, particularly in the area of cardiovascular treatments, contributes to this growth[5].

Generic Market

Nicardipine hydrochloride has been available in generic forms since the early 2000s, with multiple ANDAs (Abbreviated New Drug Applications) submitted and approved. This generic competition can influence pricing and market share but also ensures a steady supply of the drug[5].

Market Segmentation

The market can be segmented based on the type of formulation (e.g., Cardene In 5.0% Dextrose In Plastic Container) and the geographical region. The demand for intravenous formulations like Cardene is particularly high in hospital settings and intensive care units.

Market Projections

Growth Drivers

Several factors are expected to drive the growth of the nicardipine hydrochloride market:

  • Increasing Prevalence of Hypertension: The rising incidence of hypertension and other cardiovascular diseases is expected to increase the demand for antihypertensive medications like nicardipine hydrochloride.
  • Advancements in Healthcare: Improvements in healthcare infrastructure and access to medical services, especially in developing countries, will further boost the market.
  • Generic Competition: The availability of generic versions of nicardipine hydrochloride will continue to drive market growth by offering cost-effective alternatives to branded products[5].

Challenges

Despite the growth potential, there are challenges to consider:

  • Stability Issues: The instability of nicardipine hydrochloride in certain solutions can affect its shelf life and clinical efficacy, necessitating careful handling and storage.
  • Regulatory Compliance: Manufacturers must adhere to stringent regulatory requirements, which can impact production and distribution.

Competitive Landscape

Key Players

The market for nicardipine hydrochloride includes several key players, both branded and generic. Companies like Bausch Health (formerly Valeant Pharmaceuticals) have been significant players in the market. Generic manufacturers also play a crucial role in providing affordable alternatives[5].

Market Share

The market share is distributed among branded and generic manufacturers. Generic versions, due to their cost-effectiveness, often capture a significant portion of the market share.

Future Outlook

Technological Advancements

Future advancements in formulation technology could improve the stability and efficacy of nicardipine hydrochloride. For instance, new container materials or formulations that enhance stability in various solutions could be developed.

Regulatory Updates

Regulatory updates and changes in FDA guidelines can impact the market. For example, any new requirements for stability testing or clinical trials could influence the development and approval process for new formulations.

Global Expansion

The global expansion of healthcare services and the increasing demand for cardiovascular treatments in emerging markets are expected to drive the growth of the nicardipine hydrochloride market.

Key Takeaways

  • Stability Concerns: Nicardipine hydrochloride has stability issues in certain intravenous solutions, which must be addressed to ensure efficacy.
  • Market Growth: The market is expected to grow due to increasing demand, favorable market dynamics, and the expanding healthcare sector.
  • Generic Competition: Generic versions of nicardipine hydrochloride play a significant role in the market, offering cost-effective alternatives.
  • Future Advancements: Technological advancements and regulatory updates will shape the future of the nicardipine hydrochloride market.

FAQs

What is the primary use of Cardene In 5.0% Dextrose In Plastic Container?

Cardene In 5.0% Dextrose In Plastic Container is primarily used as an antihypertensive medication due to its calcium channel blocking and vasodilator properties.

Why is stability testing important for nicardipine hydrochloride?

Stability testing is crucial to ensure that the drug remains effective and safe for use. Nicardipine hydrochloride has been shown to be unstable in certain solutions, which can affect its clinical efficacy.

What are the growth drivers for the nicardipine hydrochloride market?

The growth drivers include the increasing prevalence of hypertension, advancements in healthcare, and the availability of generic versions of the drug.

Who are the key players in the nicardipine hydrochloride market?

Key players include both branded and generic manufacturers, with companies like Bausch Health and various generic manufacturers playing significant roles.

What are the potential challenges for the nicardipine hydrochloride market?

Challenges include stability issues, regulatory compliance, and the need for careful handling and storage to maintain the drug's efficacy.

Sources

  1. Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 - Not directly relevant but provides context on clinical trial design and FDA interactions.
  2. Cardene In 4.8% Dextrose In Plastic Container - Provides detailed chemical and pharmaceutical information about Cardene.
  3. Stability of nicardipine hydrochloride in intravenous solutions - Critical for understanding the stability of the drug in various solutions.
  4. Cadrenal Therapeutics Provides 2024 Year-End Company Update - Not directly relevant but offers insights into clinical trial processes and FDA interactions.
  5. NICARDIPINE HYDROCHLORIDE - Generic Drug Details - Provides market and regulatory information about nicardipine hydrochloride.
Last updated: 2025-01-03

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.